Microfluidic gut-axis-on-a-chip models for pharmacokinetic-based disease models.

Area of Science:

• Biomedical Engineering
• Pharmacology
• Toxicology

Background:

• Traditional animal models have low success rates for predicting human drug responses.
• Multi-organ-on-a-chip technology offers advanced in vitro platforms for studying organ interactions.
• The gut-liver axis is critical for nutrient absorption, drug metabolism, and immune responses.

Purpose of the Study:

• To review the components and functions of the gut-liver axis.
• To explore the potential of gut-liver-on-a-chip models for simulating gut-liver interactions.
• To discuss future directions for physiologically relevant gut-liver models in drug development and disease research.

Main Methods:

• Discussion of key components: gut epithelium, liver cells, and gut microbiota.
• Exploration of gut-liver-on-a-chip system designs and capabilities.
• Review of applications in pharmacokinetics, drug development, and disease modeling.

Main Results:

• Gut-liver-on-a-chip models can replicate complex gut-liver interactions.
• These models show promise for improving pharmacokinetic predictions.
• Expansion to multi-organ models can further enhance physiological relevance.

Conclusions:

• Gut-liver-on-a-chip models are essential for accurate drug development.
• These systems can advance the study of liver diseases and personalized treatments.
• Future research should focus on creating more complex and physiologically representative models.